Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma

Jessica Latchman, Ann Guastella, Cindy Tofthagen

Research output: Contribution to journalArticle

Abstract

Checkpoint inhibitors are a form of immunotherapy that have revolutionized treatment for malignant melanoma, resulting in longer survival and better disease control. Multiple autoimmune disorders can occur with the use of checkpoint inhibitors, including severe, potentially fatal neurologic complications. Although neurologic complications are uncommon, their early recognition and treatment is required. The purpose of this article is to present information on neurologic complications of ipilimumab and nivolumab to inform nursing practice. Recommendations for evaluation and treatment of neurologic complications are reviewed.

Original languageEnglish (US)
Pages (from-to)355-358
Number of pages4
JournalClinical journal of oncology nursing
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2019

Fingerprint

Nervous System
Melanoma
Therapeutics
Immunotherapy
Nursing
Survival
ipilimumab
nivolumab

Keywords

  • immunotherapy
  • management
  • melanoma
  • neurologic complications
  • side effects

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Neurologic Complications : Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma. / Latchman, Jessica; Guastella, Ann; Tofthagen, Cindy.

In: Clinical journal of oncology nursing, Vol. 23, No. 4, 01.08.2019, p. 355-358.

Research output: Contribution to journalArticle

@article{6002260bc863457194b2b6ab725b02d0,
title = "Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma",
abstract = "Checkpoint inhibitors are a form of immunotherapy that have revolutionized treatment for malignant melanoma, resulting in longer survival and better disease control. Multiple autoimmune disorders can occur with the use of checkpoint inhibitors, including severe, potentially fatal neurologic complications. Although neurologic complications are uncommon, their early recognition and treatment is required. The purpose of this article is to present information on neurologic complications of ipilimumab and nivolumab to inform nursing practice. Recommendations for evaluation and treatment of neurologic complications are reviewed.",
keywords = "immunotherapy, management, melanoma, neurologic complications, side effects",
author = "Jessica Latchman and Ann Guastella and Cindy Tofthagen",
year = "2019",
month = "8",
day = "1",
doi = "10.1188/19.CJON.355-358",
language = "English (US)",
volume = "23",
pages = "355--358",
journal = "Clinical Journal of Oncology Nursing",
issn = "1092-1095",
publisher = "Oncology Nursing Society",
number = "4",

}

TY - JOUR

T1 - Neurologic Complications

T2 - Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma

AU - Latchman, Jessica

AU - Guastella, Ann

AU - Tofthagen, Cindy

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Checkpoint inhibitors are a form of immunotherapy that have revolutionized treatment for malignant melanoma, resulting in longer survival and better disease control. Multiple autoimmune disorders can occur with the use of checkpoint inhibitors, including severe, potentially fatal neurologic complications. Although neurologic complications are uncommon, their early recognition and treatment is required. The purpose of this article is to present information on neurologic complications of ipilimumab and nivolumab to inform nursing practice. Recommendations for evaluation and treatment of neurologic complications are reviewed.

AB - Checkpoint inhibitors are a form of immunotherapy that have revolutionized treatment for malignant melanoma, resulting in longer survival and better disease control. Multiple autoimmune disorders can occur with the use of checkpoint inhibitors, including severe, potentially fatal neurologic complications. Although neurologic complications are uncommon, their early recognition and treatment is required. The purpose of this article is to present information on neurologic complications of ipilimumab and nivolumab to inform nursing practice. Recommendations for evaluation and treatment of neurologic complications are reviewed.

KW - immunotherapy

KW - management

KW - melanoma

KW - neurologic complications

KW - side effects

UR - http://www.scopus.com/inward/record.url?scp=85070072662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070072662&partnerID=8YFLogxK

U2 - 10.1188/19.CJON.355-358

DO - 10.1188/19.CJON.355-358

M3 - Article

C2 - 31322610

AN - SCOPUS:85070072662

VL - 23

SP - 355

EP - 358

JO - Clinical Journal of Oncology Nursing

JF - Clinical Journal of Oncology Nursing

SN - 1092-1095

IS - 4

ER -